XML 40 R31.htm IDEA: XBRL DOCUMENT v3.25.1

Collaboration Agreements, License Agreement and Revenues (Tables)

12 Months Ended

Dec. 31, 2024

Schedule of Drug Product Revenue

Drug product revenue from commercial-grade API or bulk drug product sales to Astellas and AstraZeneca was as follows for the years ended December 31, 2024 and 2023 (in thousands):

		Years Ended December 31,
		2024				2023
Astellas Japan Agreement		$	(2,872	)		$	15,656
Astellas Europe Agreement			4,874				3,097
AstraZeneca U.S./RoW Agreement			25,671				—
Drug product revenue, net		$	27,673			$	18,753

Summary of Amounts Recognized as Revenue

Amounts recognized as revenue under the agreements with Eluminex were as follows for the years ended December 31, 2024 and 2023 (in thousands):

				Years Ended December 31,
Agreement		Performance Obligation		2024				2023
Eluminex		License revenue		$	—			$	7,000
		Other revenue - contract manufacturing		$	117			$	966
		Other revenue - patent transfer		$	—			$	500

AstraZeneca Agreements [Member]

Roll-forward of Related Contract Liabilities

The following table includes a roll-forward of the related deferred revenue that is considered as a contract liability (in thousands):

		Balance at December 31, 2023				Additions				Recognized as Revenue (Discontinued Operations)				Currency Translation and Other				Balance at December 31, 2024
AstraZeneca China performance obligation    - deferred revenue		$	(179,851	)		$	(112,503	)		$	159,010			$	1,247			$	(132,097	)

Drug Product Revenue, Net [Member]

Roll-forward of Related Contract Liabilities

The following table includes a roll-forward of the above-mentioned deferred revenues that are considered as contract liabilities related to drug product (in thousands):

		Balance at December 31, 2023				Additions				Recognized as Revenue				Reclassified to Accrued Liability / Accounts Payable				Balance at December 31, 2024
Drug product revenue - deferred revenue:
Astellas Europe Agreement		$	(16,925	)		$	(4,441	)		$	4,295			$	7,170			$	(9,901	)

Europe [Member]

Summary of License Revenue and Development Revenue Recognized under Agreement

Amounts recognized as license revenue and development revenue under the Astellas Europe Agreement were as follows for the years ended December 31, 2024 and 2023 (in thousands):

				Years Ended December 31,
Agreement		Performance Obligation		2024				2023
Astellas Europe Agreement		Development revenue		$	1,395			$	6,452

U.S./RoW and China [Member]

Summary of License Revenue and Development Revenue Recognized under Agreement

Amounts recognized as license revenue and development revenue under the AstraZeneca U.S./RoW Agreement and the AstraZeneca China Agreement were as follows for the years ended December 31, 2024 and 2023 (in thousands):

				Years Ended December 31,
Agreement		Performance Obligation		2024				2023
AstraZeneca U.S./RoW Agreement and AstraZeneca China Agreement		License revenue		$	—			$	2,649
		Development revenue		$	418			$	9,473

X

- Definition

Contract with customer milestone method.

+ References

No definition available.

+ Details

Name:	fgen_ContractWithCustomerMilestoneMethodTableTextBlock
Namespace Prefix:	fgen_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Schedule of drug product revenue.

+ References

No definition available.

+ Details

Name:	fgen_ScheduleOfDrugProductRevenueTableTextBlock
Namespace Prefix:	fgen_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.

+ References

No definition available.

+ Details

Name:	us-gaap_DeferredRevenueByArrangementDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: